866-997-4948(US-Canada Toll Free)

Fragile X Syndrome - Pipeline Review, H1 2017

Published By :

Global Markets Direct

Published Date : Apr 2017

Category :

Diseases & Conditions

No. of Pages : 108 Pages

Fragile X Syndrome - Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Fragile X Syndrome - Pipeline Review, H1 2017, provides an overview of the Fragile X Syndrome (Genetic Disorders) pipeline landscape.

Gastric ulcer is a painful sore or ulcer in the lining of stomach. The most common cause of gastric ulcer is Helicobacter pylori bacterial infection. Symptoms include pain, bloating, retching, nausea or vomiting and unexplained weight loss. Predisposing factors include smoking and alcoholism. Treatment includes antibiotics and antacids.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Fragile X Syndrome - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Fragile X Syndrome (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Fragile X Syndrome (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Fragile X Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 3, 13 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 2 molecules, respectively.

Fragile X Syndrome (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Fragile X Syndrome (Genetic Disorders).
- The pipeline guide reviews pipeline therapeutics for Fragile X Syndrome (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Fragile X Syndrome (Genetic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Fragile X Syndrome (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Fragile X Syndrome (Genetic Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Fragile X Syndrome (Genetic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Fragile X Syndrome (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Fragile X Syndrome - Overview 6
Fragile X Syndrome - Therapeutics Development 7
Pipeline Overview 7
Pipeline by Companies 8
Pipeline by Universities/Institutes 10
Products under Development by Companies 11
Products under Development by Universities/Institutes 13
Fragile X Syndrome - Therapeutics Assessment 14
Assessment by Target 14
Assessment by Mechanism of Action 16
Assessment by Route of Administration 18
Assessment by Molecule Type 20
Fragile X Syndrome - Companies Involved in Therapeutics Development 22
Aelis Farma SAS 22
AMO Pharma Ltd 22
Anavex Life Sciences Corp 23
Confluence Pharmaceuticals LLC 23
DRI Biosciences Corp 24
Eli Lilly and Company 24
Fulcrum Therapeutics Inc 25
GlaxoSmithKline Plc 25
GW Pharmaceuticals Plc 26
Marinus Pharmaceuticals Inc 26
Neuren Pharmaceuticals Ltd 27
Neuron Biopharma SA 27
Ovid Therapeutics Inc 28
Sage Therapeutics Inc 28
Zynerba Pharmaceuticals Inc 29
Fragile X Syndrome - Drug Profiles 30
acamprosate calcium - Drug Profile 30
ACT-01 - Drug Profile 31
AMO-01 - Drug Profile 32
ANAVEX-273 - Drug Profile 34
Bryostatin-1 - Drug Profile 44
cannabidiol - Drug Profile 49
cercosporamide - Drug Profile 54
Drug to Antagonize mGluR5 for Fragile X Syndrome and 16p11.2 Microdeletion Syndrome - Drug Profile 56
flindokalner - Drug Profile 57
gaboxadol - Drug Profile 58
ganaxolone - Drug Profile 60
JRP-655 - Drug Profile 67
NNZ-2591 - Drug Profile 68
NST-0076 - Drug Profile 70
SAGE-217 - Drug Profile 71
SGE-872 - Drug Profile 74
Small Molecule for Fragile X-Associated Tremor Ataxia Syndrome - Drug Profile 75
Small Molecule to Activate FMRP for Fragile X Syndrome - Drug Profile 76
Small Molecule to Antagonize CB1R for Fragile X Syndrome and Down Syndrome - Drug Profile 77
Small Molecules to Activate Slack Channels for Fragile X Syndrome - Drug Profile 78
Small Molecules to Agonize Cannabinoid Receptor 2 for Fragile X Syndrome, Pervasive Developmental Disorder and Rett Syndrome - Drug Profile 79
Small Molecules to Block Kv3.1 for Fragile X Syndrome - Drug Profile 80
Small Molecules to Inhibit PI3K for Autism and Fragile X Syndrome - Drug Profile 81
SRT-278 - Drug Profile 82
TC-2153 - Drug Profile 83
trofinetide - Drug Profile 84
Fragile X Syndrome - Dormant Projects 92
Fragile X Syndrome - Discontinued Products 94
Fragile X Syndrome - Product Development Milestones 95
Featured News & Press Releases 95
Appendix 105
Methodology 105
Coverage 105
Secondary Research 105
Primary Research 105
Expert Panel Validation 105
Contact Us 105
Disclaimer 106

List of Tables
Number of Products under Development for Fragile X Syndrome, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Fragile X Syndrome - Pipeline by Aelis Farma SAS, H1 2017
Fragile X Syndrome - Pipeline by AMO Pharma Ltd, H1 2017
Fragile X Syndrome - Pipeline by Anavex Life Sciences Corp, H1 2017
Fragile X Syndrome - Pipeline by Confluence Pharmaceuticals LLC, H1 2017
Fragile X Syndrome - Pipeline by DRI Biosciences Corp, H1 2017
Fragile X Syndrome - Pipeline by Eli Lilly and Company, H1 2017
Fragile X Syndrome - Pipeline by Fulcrum Therapeutics Inc, H1 2017
Fragile X Syndrome - Pipeline by GlaxoSmithKline Plc, H1 2017
Fragile X Syndrome - Pipeline by GW Pharmaceuticals Plc, H1 2017
Fragile X Syndrome - Pipeline by Marinus Pharmaceuticals Inc, H1 2017
Fragile X Syndrome - Pipeline by Neuren Pharmaceuticals Ltd, H1 2017
Fragile X Syndrome - Pipeline by Neuron Biopharma SA, H1 2017
Fragile X Syndrome - Pipeline by Ovid Therapeutics Inc, H1 2017
Fragile X Syndrome - Pipeline by Sage Therapeutics Inc, H1 2017
Fragile X Syndrome - Pipeline by Zynerba Pharmaceuticals Inc, H1 2017
Fragile X Syndrome - Dormant Projects, H1 2017
Fragile X Syndrome - Dormant Projects, H1 2017 (Contd..1), H1 2017
Fragile X Syndrome - Discontinued Products, H1 2017

List of Figures
Number of Products under Development for Fragile X Syndrome, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Number of Products by Top 10 Targets, H1 2017
Number of Products by Stage and Top 10 Targets, H1 2017
Number of Products by Top 10 Mechanism of Actions, H1 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Routes of Administration, H1 2017
Number of Products by Molecule Types, H1 2017
Number of Products by Stage and Molecule Types, H1 2017

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *